Clinical. Off-label and Unlicensed Medicines Policy. Document Control Summary. Contents

Size: px
Start display at page:

Download "Clinical. Off-label and Unlicensed Medicines Policy. Document Control Summary. Contents"

Transcription

1 Clinical Off-label and Unlicensed Medicines Policy Document Control Summary Status: Version: Author/Owner/Title: Approved by: Ratified: Related Trust Strategy and/or Strategic Aims Implementation Date: Review Date: Key Words: Associated Policy or Standard Operating Procedures Contents Replacement superseding the Policy for Medicines Used Outside Terms of Product Licence or Without a Product Licence. 6.1 Date: December 2016 Mo Azar Policy and Procedures Committee Date: 23 March 17 Trust Board Date: 30 March 17 Medicines Optimisation Strategy 2013 to 2018 January 2017 January 2020 product licence, high dose antipsychotics (HDAP), monitoring, approved list, unlicensed medicines, SPC, off-label. Medicines Code Trust Formulary Non-Medical Prescribing Policy Medicines Used Outside Product Licence Approved List Medicines Used Outside Product Licence Notification Form Medicines Used Outside Product Licence Patient Leaflet High Dose Antipsychotics Prescribing SOP High Dose Antipsychotics Monitoring Form 1. Introduction Purpose Scope Responsibilities Specific Guidance Process for Monitoring Compliance and Effectiveness References... 7 Appendix 1: Royal College Guidelines... 8

2 Appendix 2: Approved List Appendix 3: Notification Form Change Control Amendment History Version Dates Amendments 6 December 2015 Converted to Trust s approved layout. NMP and Pharmacy responsibilities added. Clinical trial medication added and cross-referenced to Research and Innovation procedures. Approved List updated to include GUM service s prescribing. High Dose Antipsychotic guidance removed to separate SOP Page 2 of 16

3 1. Introduction For a medicine to be marketed in the United Kingdom, it must have a Product Licence, now called a Marketing Authorisation, which is overseen by the Medicines and Healthcare Products Regulatory Agency (MHRA). It is then classed as a licensed medicine. The licence will normally specify the indication, route, dose, and age range of the patients for which the medicine is intended to be used. The Medicines Act (1968) and other associated regulations provide specific exemptions which enable prescribers to: Use (or advise the use of) medicines for indications, doses, routes of administration outside the recommendations of the licence. Override the warnings and precautions given in the licence Use (or advise the use of) medicines for which there is no Marketing Authorisation in the United Kingdom i.e. an unlicensed medicine. These items may require importing to the United Kingdom via specialist wholesalers and permission from the MHRA. In each case the prescriber has to be able to justify the action taken as being in accordance with a respected, responsible body of professional opinion. The prescriber should also be able to justify their selection of a drug in light of an informed risk/benefit assessment. In secondary care, it is common practice to use medicines outside their product licence, often due to a pharmaceutical company's decision not to seek such a licence in a limited group of patients or conditions; unlicensed medicines may also be prescribed by specialists. In most cases there is adequate expert opinion to support such use. In some fields of practice, e.g. paediatrics and learning disabilities, there may be only a few medicines actually fully licensed and marketed for use. The majority of treatments being used will fall outside the terms of the product licence, or may not even have a UK licence, but nevertheless it is still good medical practice to use them. Informed consent to treatment is a key area of prescribing. However, consent to a medicine being used outside of its product licence or without a licence is difficult, as misunderstandings of a medicine s safety profile might undermine a patient's confidence, causing unnecessary alarm. The unlicensed situation may be because of lack of clinical data, or be economically unfeasible to obtain, rather than evidence of harm. Nevertheless, a patient or their carer has the right to participate in decisions regarding healthcare, including having the knowledge of a drug's licensed indications. Patients have a right to a Patient Information Leaflet (PIL) with their dispensed medicine and the licensing criteria will be stated in this document rather than the purposes discussed with the prescriber. This may lead to a patient deciding not to take a particular medicine. In this situation, it will therefore almost always be beneficial to raise the licensing issue when the medicine is prescribed. An information leaflet is available from the Trust to support this matter. This policy should be read in conjunction with all medicines policies and procedures, particularly the Medicines Code and Trust Formulary. Non-medical prescribers should also refer to the Non-Medical Prescribing Policy and associated procedures. Page 3 of 16

4 2. Purpose This policy aims to ensure that when medicines are used outside of their product licence ( off-label ) or without a product licence (unlicensed), patients are appropriately informed, and that clinical risks and liability for the Trust are minimised. 3. Scope This policy applies to all prescribers working within the Trust. Non-medical prescribers (NMPs) may also prescribe medicines outside the terms of, or without, a product licence provided that they work within the scope of their formulary and in accordance with the Non- Medical Prescribing Policy. Pharmacy and Medicines Optimisation Department staff will also need to ensure the additional documentation required when dispensing unlicensed medicines is completed and that all reasonable steps are taken to source products with a UK Marketing Authorisation where such products exist. Pharmacy and Medicines Optimisation department staff should be prepared to challenge the prescribing of medicines outside the terms of, or without, a product licence where it is not considered usual practice to prescribe such items. Neither they nor the Trust are liable for the decision to prescribe medicines described in this Policy and full liability remains with the individual prescriber. 4. Responsibilities Prescribers should, whenever possible, prescribe medicines that are appropriately licensed for the condition and patient they are intending to treat and should follow the manufacturer s recommendations. If prescribing outside or without a product licence, prescribers should follow the guidelines in an established reference source. Ideally, this would be from published prescribing guidelines including those published by NICE, although it could be from a scientific paper from a reputable journal. Prescribers should follow advice from their Royal College (Appendix 1). Normally, only consultants, associated specialists, GPs with Special Interest or independent non-medical prescribers (when working within their own formulary) should initiate prescribing outside or without a product licence; the prescribing should be within their field of expertise. Junior medical staff or supplementary non-medical prescribers may only initiate prescribing outside of a medicine s product licence, or a product without a licence, if there is an established protocol that has been endorsed by a medical consultant or clinical lead. The Medicines Optimisation Committee should be notified of such practice unless the medication/indication appears in the approved list associated with this policy and is being prescribed in the stated manner. Junior medical staff prescribing ongoing off-label or unlicensed treatment may do so provided it is still within the specialist s ongoing treatment plan. They should, however, be aware of their own liability around the prescribing of such treatments. Page 4 of 16

5 Service users and/or their carers should be informed of the reason why the treatment is being used and should be informed that the Patient Information Leaflet, within the medicines pack, might not be in accordance with the prescriber's intended use of the drug. They should be offered the Trust s Unlicensed Medication leaflet as part of the consultation process to support this explanation. The Pharmacy and Medicines Optimisation Department (or community pharmacist) has a responsibility of notifying a prescriber if a medicine requested is clearly being used significantly outside the terms of its product licence, or without a product licence, and there is no clear precedent for its use. The prescriber has a responsibility to the Trust of justifying his/her action, and this being subject to scrutiny by the Medicines Optimisation Committee. However, if such use is likely to be fairly common practice it would be more appropriate for the medication or indication to be added to the approved list associated with this policy (Appendix 2). Such cases should be made by the specialist to the chair of Medicines Optimisation Committee (or nominated deputy) and will only be added to the approved list if supporting evidence is provided and it is agreed by the Committee. Whether advised by the Pharmacy and Medicines Optimisation Department or not, if prescribing a medicine subject to this policy but not included on the approved list, Trust prescribers are required to complete a Medicines Used Outside of a Product Licence Notification Form (Appendix 3), and submit it to the Director of Pharmacy (or nominated deputy). Such instances will be noted by the Medicines Optimisation Committee to provide the opportunity for peer review scrutiny within the Trust. In all cases of prescribing off-label or unlicensed medicines (whether on the approved list or not and irrespective of noting by the Committee), the prescriber retains full responsibility for their clinical decisions made in this area. Investigational Medicinal Products (IMPs) being prescribed as part of a formal clinical trial will be dealt with separately as part of the Research and Innovation Department s agreed policies and procedures in accordance with Good Clinical Practice standards. As part of the approval process, the trial will be assessed at the Medicines Optimisation Committee and prescribing will be limited to those on the Principal Investigator s delegation log. Patients admitted to Trust premises who are taking part in another organisation s clinical trial may continue to take part in that study provided: it is appropriate, the study team are aware of the situation and that the case has been brought to the attention of both the Research and Innovation Department and the Pharmacy and Medicines Optimisation Department. If it is the intention that the drug is to be prescribed in primary care, then the GP must be informed of the unlicensed or off-label use of the medicine by the Trust prescriber; NB GPs may not be prepared to prescribe such products. In these cases, the Trust prescriber should initially offer the availability of an Essential Shared Care Agreement (ESCA), previously approved by the Trust and relevant Clinical Commissioning Group, to further support the GP in taking on prescribing responsibility; support is available from the Pharmacy and Medicines Optimisation Department. If the GP refuses to prescribe the treatment (as is their right) then the Trust prescriber will be expected to continue with the long-term prescribing. In situations where an ESCA is available, complete an ESCA refusal form and send to the Pharmacy and Medicines Optimisation Department. In situations Page 5 of 16

6 where there is no ESCA in place, the unlicensed/off-label treatment should remain with the specialist and not be transferred to primary care. 5. Specific Guidance The majority of medicines used within adult mental health, inclusion and sexual health services have a Marketing Authorisation, which sets out the manufacturer s conditions of use and for which, if followed, they will take legal liability for the safety of the product. The prescriber is still liable for the use of the medicines they prescribe (as per Good Medical Practice). If a medicine is prescribed for a condition for which it is not licensed then the prescriber must take full legal responsibility for the product as well. A drug can be mentioned in the BNF but not have a licence. It is possible to access up-to-date Summaries of Product Characteristics (Product Licence information) for medicines on the electronic medicines compendium Prescribers may recommend the use of medicines outside their licence ( off label ). In such cases, the evidence will have been assessed and a judgement made that the use of such medications is of benefit to the service user, outweighing any risks that might apply. The service user should be fully informed of the benefits and adverse effects of the medication. The Trust has agreed to support prescribers carry out their standard practice by acknowledging the use of a limited list of treatments (both unlicensed medicines for the listed indications, or unlicensed uses of licensed medication) as they can occur commonly and have evidence to support their use; individual notifications to the Medicines Optimisation Committee are not required in these instances. However, the Trust does not: accept liability for their use; seek to promote as a corporate body their use; and does not consider the list suitable for citing as a reference by another person or organisation. The intention of the list is solely to reduce internal procedural burden for prescribers undertaking standard practice. The off-label use of licensed medicines within Child and Adolescent Mental Health Services is also supported by the Trust, when used in concordance with the current version of the BNF for Children. The use of medicines within the Community Paediatrics service and Community Children s Nursing team is so specialised that it would be impractical to set an approved list. Paediatricians are advised to follow the guidance from their Royal College. Children s nurses should liaise with the specialist paediatricians and the Pharmacy and Medicines Optimisation Department to maintain and follow a local formulary and any specific shared care protocols approved by the Medicines Optimisation Committee. The list is constantly under review; please contact the Director of Pharmacy and Medicines Optimisation (or nominated deputy) if it is felt that there are any inaccuracies or medicines/indications that should be included or removed. 6. Process for Monitoring Compliance and Effectiveness This policy will be monitored by the Medicines Optimisation Committee through submission of Medicines Used Outside of Product Licence Forms and requests for amendment to the Page 6 of 16

7 approved list, clinical pharmacist supervision identifying trends in practice and information obtained from prescription data / prescribing indicator reports. When dispensing unlicensed medicinal products, the Trust s dispensary teams will follow their local procedure and document the supplies made as stipulated by the MHRA and retain those records for the required period of five years from the last entry. 7. References Medicines Act 1968 and Regulations. The Use of Unlicensed Medicines or Licensed Medicines for Unlicensed Applications in Paediatric Practice, Policy Statement. Royal College of Paediatrics and Child Health and Neonatal and Paediatrics Pharmacist Group Standing Committee on Medicines. December Use of Licensed Medicines for Unlicensed Applications in Psychiatric Practice. CR142, Royal College of Psychiatrists, January Good Medical Practice: Prescribing and Managing Medicines and Devises: Prescribing Unlicensed Medicines. General Medical Council, The Supply of Unlicensed Medicinal Products (specials). Guidance Note 14, Medicines and Healthcare Regulatory Agency, May Page 7 of 16

8 Appendix 1: Use of unlicensed medicines or licensed medicines for unlicensed applications (Royal Colleges) Summary of the recommendations from the joint Royal College of Paediatrics and Child Health and the Neonatal and Paediatric Pharmacists Group standing committee on medicines (Royal College of Paediatrics and Child Health, 2013) Those who prescribe for a child should choose the medicine which offers the best prospect for that child, aware that such prescribing may be constrained by the availability of resources. Children should be able to receive medicines that are safe, effective, appropriate for their condition, palatable and available with minimal clinical risk. The informed use of some unlicensed medicines or licensed medicines for unlicensed applications is necessary in paediatric practice. Health professionals should have access to reliable and up-to-date information, where possible, on any medicine they prescribe, dispense or administer, and on its availability. In general, it is not necessary to take additional steps, beyond those taken when prescribing licensed medicines, to obtain the consent of parents, carers and child patients to prescribe or administer unlicensed medicines or licensed medicines for unlicensed applications. NHS Organisations should support therapeutic practices that are advocated by a respectable, responsible body of professional opinion. Where available, an appropriate licensed preparation should be prescribed and supplied in preference to an unlicensed preparation. Use of licensed medicines for unlicensed applications in psychiatric practice (CR142, Royal College of Psychiatrists, January 2007) 1) Check that medicines with a product licence have either had a proper therapeutic trial or been considered, but excluded on clinical grounds (such as contraindications and risk of interactions). 2) Familiarise yourself with the evidence about the proposed drug, including any possible drug interactions and potential adverse effects. 3) If the medicine to be used does not have a substantial evidence base supporting its use for the proposed indication, or if you are not sufficiently expert in this field, or have particular concerns, obtain the advice of another doctor or specialist pharmacist. 4) Consider the risks and benefits of the proposed treatment. Particular consideration is needed with children, older patients, and in those with impaired insight and judgement. Document this. 5) Give the patient (or his/her relative, when relevant) a full explanation, including the information that the drug will be used outside its product licence. Document this explanation. 6) If agreement from the patient (or his/her relative, when needed) is obtained, document this approval. If a patient is unable to consent to a necessary treatment, note that it has not been possible to obtain consent. 7) Begin a cautious trial of treatment with the medicine. In out-patients, consider sending the patient a copy of any letter sent to his/her general practitioner, summarising why this approach has been adopted. 8) Monitor the patient closely. Continue with full documentation of its effectiveness and tolerance. Page 8 of 16

9 9) If the treatment proves unsuccessful, withdraw it, gradually if needed. Document the reason for the withdrawal of treatment and then consider alternatives, using the same process. 10) Consider writing up the case, to add to knowledge about the drug and its use. Page 9 of 16

10 Appendix 2: Medicines Used Outside Product License Approved List Mental Health Services Drug or Group Unlicensed condition or use Comments Antidepressants Anxiety/ Panic disorder Some licensed for these indications; try these first All antipsychotics Excluding new products subject to a managed entry scheme within the Trust where specific criteria are in place Risperidone Doses above SPC limits (as single agents or in combination) Use in bipolar affective disorder and schizoaffective disorder Insomnia (in individuals prone to dependence with hypnotics), agitation, anxiety, aggression Adults with a learning difficulty with behavioural problems Tourette s and other tic disorders In accordance with Royal College of Psychiatrists advice and Trust guidance: High Dose Antipsychotic Prescribing SOP. Some are licensed for mania and prophylaxis Only for short-term use (e.g. 4 weeks) with appropriate review Caution if history of stroke or TIA, or risk factors for cardiovascular disease. Atypical antipsychotics Children and adolescents Aripiprazole is licensed for Schizophrenia in adolescents aged 15 years and older and Manic episodes in Bipolar I Disorder in adolescents aged 13 years and older. Risperidone is licensed for Conduct disorder in children and adolescents from 5 to 18 years of age. Antipsychotics To manage behavioural and psychological symptoms in dementia See the Trust s Antipsychotics in Dementia Guidance. Risperidone has a very limited licence Page 10 of 16

11 Drug or Group Acetylcholinesterase inhibitors Unlicensed condition or use To manage behavioural and psychological symptoms in dementia Comments All hypnotics and benzodiazepines beyond short-term, Clonazepam (non-formulary), Midazolam (non-formulary unless buccal) Mania / acute psychiatric condition Baclofen (non-formulary) Alcohol dependence Third line When risk assessed, and involuntary addiction minimised through a clear management plan Benzodiazepines As required tranquillisation for challenging behaviour As part of Trust s rapid tranquillisation policy Memantine Lorazepam In combination with an acetylcholinesterase inhibitor This combination is excluded from the essential shared care agreement (ESCA) so prescribing remains the responsibility of the Trust Injection given orally Unlicensed injection imported during licenced version s supply problem Propranolol (non-formulary) Akathisia Buprenorphine Substance Misuse Crushing of tablets for supervised consumption in individuals known to divert medication Carbamazepine Clonazepam (non-formulary) Bipolar affective disorder (non-lithium resistant cases) Aggression and impulsive behaviour Behavioural control Anxiety Tardive dyskinesia REM Sleep Behaviour Only licensed for use in lithium non-responsive cases Page 11 of 16

12 Drug or Group Clonidine Methylphenidate Hyoscine hydrobromide (Kwells, Scopoderm patches), Pirenzepine Unlicensed condition or use Disorder in Parkinson s and Dementia with Lewy Bodies ADHD and Tourette s Treatment of ADHD in working age adults Hypersalivation Comments Skills and supervision arrangements required. ESCAs are developed for adult use for Methylphenidate, Atomoxetine and Dexamfetamine Side effect of antipsychotics esp. clozapine. See hypersalivation guidance within the clozapine policy. (Other unlicensed treatments included within this guide). Lamotrigine Modafinil (non-formulary) Beta blockers Sodium Valproate (Epilim) (all formulations) Wider use in bipolar affective disorder Sleep problems in Parkinson s Tachycardia when seen as a side effect of clozapine Use in bipolar affective disorder Licensed for prevention of depressive episodes in bipolar I only Midazolam Status epilepticus Buccal Licensed product: Buccolam preferred Diazepam Melatonin Rescue medication for clusters of epileptic seizures Insomnia in children and adolescents, and adult users of DNLD services (without Oral instead of rectal is useful in patients who are having repeated seizures with complete recovery in between. See ESCA and Prescribing Guidance. Licensed product (Circadin) preferred for off- Page 12 of 16

13 Drug or Group All medicines containing nonsustained release ingredients, where safety and appropriateness have been discussed with pharmacy Quetiapine Intravenous fluids: Sodium Chloride 0.9% Glucose 5% Unlicensed condition or use primary insomnia). Crushed Please check with Pharmacy before crushing any medicines All indications for modifiedrelease (XL) formulation being used with the immediate release formulation. Sub-cutaneous administration Comments label use, rather than unlicensed products. For patients under the MHA 1983, if non-concordant and necessary. NOT COVERT. For physical health treatments (and also for other informal patients) administered under the Mental Capacity Act. Includes covert use see separate guidance. For patients who have a swallowing difficulty. For management of dehydration i.e. hypodermoclysis GUM/SHS Services Drug or Group Unlicensed condition or use Comments Benzathine Penicillin Syphilis Standard antibacterial treatment for syphilis Clobetasol Propionate 0.05% cream or ointment Tricholoracetic Acid 90% Solution Post Exposure Prophylaxis (PEP) Pack Vulval Conditions (Genital dermatosis, lichen sclerosis, lichen planus) Chemical cauterisation of anogenital warts HIV prophylaxis Ointment generally preferred, creams have preservatives which can be irritant For use in specialist setting only Special packs procured which utilise licensed Page 13 of 16

14 Drug or Group Truvada (245mg tenofovir disoproxil and 200mg emtricitabine) + raltegravir Spectinomycin 2g injections Unlicensed condition or use Gonorrhoea In Penicillin allergy / resistant cases Comments products packed down for specific courses. Spectinomycin resistance is very rare Page 14 of 16

15 Appendix 3 Patient NHS number: Date of Initiation: Medicines Used Outside Terms Of Or Without a Product Licence (apart from those on the Trust Approved List) Name of Prescribing Clinician: Contact Details of Requesting Consultant: Drug Prescribed: Please state formulation and strength Indication for Prescription: Dose, Frequency & Route: This Represents (pls tick) Outside of Manufacturers Normal Recommendations An Unlicensed Product Rationale for Unlicensed or Off Label Use: Please give full information so that the rationale can be understood If you are following an agreed protocol or reference source, could you please supply details Once complete please return to pharmacy Page 15 of 16

16

Clinical. Off-label and Unlicensed Medicines Policy. Document Control Summary. Contents

Clinical. Off-label and Unlicensed Medicines Policy. Document Control Summary. Contents Clinical Off-label and Unlicensed Medicines Policy Document Control Summary Status: Version: Author/Owner/Title: Approved by: Ratified: Related Trust Strategy and/or Strategic Aims Implementation Date:

More information

SHARED CARE GUIDELINE

SHARED CARE GUIDELINE SHARED CARE GUIDELINE Title: Shared Care Guideline for the prescribing and monitoring of Antipsychotics for the treatment of Schizophrenia and psychotic symptoms in children and adolescents Scope: Pennine

More information

Buccal Midazolam For the treatment of prolonged epileptic seizures, clusters of epileptic seizures and status epilepticus.

Buccal Midazolam For the treatment of prolonged epileptic seizures, clusters of epileptic seizures and status epilepticus. Oxfordshire Clinical Commissioning Group, Oxford University Hospitals NHS Trust and Oxfordshire Health NHS Foundation Trust Shared Care Protocol and Information for GPs Buccal Midazolam For the treatment

More information

Clinical. High Dose Antipsychotic Prescribing Procedures. Document Control Summary. Contents

Clinical. High Dose Antipsychotic Prescribing Procedures. Document Control Summary. Contents Clinical High Dose Antipsychotic Prescribing Procedures Document Control Summary Status: Version: Author/Owner/Title: Approved by: Ratified: Related Trust Strategy and/or Strategic Aims Implementation

More information

SHARED CARE GUIDELINE

SHARED CARE GUIDELINE SHARED CARE GUIDELINE Shared Care Guideline for the prescribing and monitoring of antipsychotics for the treatment of Neurodevelopmental Disorders in children and adolescents. Scope: Version 1 Pennine

More information

SHARED CARE PROTOCOL FOR THE PRESCRIBING AND MONITORING OF MEDICINES FOR ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD)

SHARED CARE PROTOCOL FOR THE PRESCRIBING AND MONITORING OF MEDICINES FOR ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) SHARED CARE PROTOCOL FOR THE PRESCRIBING AND MONITORING OF MEDICINES FOR ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) 1. Introduction This protocol describes how patients prescribed medicines for ADHD

More information

GREATER MANCHESTER INTERFACE PRESCRIBING GROUP

GREATER MANCHESTER INTERFACE PRESCRIBING GROUP GREATER MANCHESTER INTERFACE PRESCRIBING GROUP On behalf of the GREATER MANCHESTER MEDICINES MANAGEMENT GROUP SHARED CARE GUIDELINE FOR THE PRESCRIBING OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)

More information

Formulary and Prescribing Guidelines

Formulary and Prescribing Guidelines Formulary and Prescribing Guidelines SECTION 3: TREATMENT OF BIPOLAR AFFECTIVE DISORDER This section provides information regarding the pharmacological management of Bipolar affective disorder in secondary

More information

T2/T3/S62/CT012 Aide Memoire

T2/T3/S62/CT012 Aide Memoire Correct way to fill out MHA forms T2/T3/S62/CTO12 SH CP 224 T2/T3/S62/CT012 Aide Memoire Version: 2 Summary: An Aide Memoire to completing or requesting a T2/T3/S62/CT012 Keywords: Target Audience: T2,

More information

E096. Essential Shared Care Agreement: Melatonin (Circadin ) in Children, adolescents and adults only with Learning Disability

E096. Essential Shared Care Agreement: Melatonin (Circadin ) in Children, adolescents and adults only with Learning Disability E096 Essential Shared Care Agreement: Melatonin (Circadin ) in Children, adolescents and adults only with Learning Disability Please complete the following details: Patient s name, address, date of birth,

More information

Methylphenidate Shared Care Agreement For attention deficit hyperactivity disorder (ADHD) in adults Effective Shared Care Agreement

Methylphenidate Shared Care Agreement For attention deficit hyperactivity disorder (ADHD) in adults Effective Shared Care Agreement Methylphenidate Shared Care Agreement For attention deficit hyperactivity disorder (ADHD) in adults Effective Shared Care Agreement Section 1: Shared Care arrangements and responsibilities Section 1.1

More information

METHYLPHENIDATE AND ATOMOXETINE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER IN CHILDREN AND YOUNG PEOPLE

METHYLPHENIDATE AND ATOMOXETINE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER IN CHILDREN AND YOUNG PEOPLE NOTTINGHAMSHIRE AREA PRESCRIBING COMMITTEE SHARED CARE PROTOCOL AGREEMENT METHYLPHENIDATE AND ATOMOXETINE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER IN CHILDREN AND YOUNG PEOPLE OBJECTIVES To

More information

PATIENT GROUP DIRECTION PROCEDURE

PATIENT GROUP DIRECTION PROCEDURE PATIENT GROUP DIRECTION PROCEDURE Date approved 2 October 2015 Version 3 Approved by Yvette Oade, Chief Medical Officer Procedure Lead Clinical Governance Lead - Medicines Management Procedure Author Karen

More information

SHARED CARE GUIDELINE FOR BUCCAL MIDAZOLAM FOR THE TREATMENT OF PROLONGED SEIZURES IN CHILDREN

SHARED CARE GUIDELINE FOR BUCCAL MIDAZOLAM FOR THE TREATMENT OF PROLONGED SEIZURES IN CHILDREN SHARED CARE GUIDELINE FOR BUCCAL MIDAZOLAM FOR THE TREATMENT OF PROLONGED SEIZURES IN CHILDREN 1. Aim/Purpose of this Guideline 1.1. This guideline applies to medical, nursing and pharmacy staff in the

More information

Shared Care Agreement for Donepezil

Shared Care Agreement for Donepezil ESCA: for the treatment of Alzheimer s disease SECONDARY CARE SECTION TO BE COMPLETED BY INITIATING DOCTOR Patient s Name: Date of Birth: NHS Number: ESCA Date: One copy of information leaflet given to

More information

USE OF UNLICENSED MEDICINES AND OFF-LABEL MEDICINES WHERE A LICENSED MEDICINE IS AVAILABLE

USE OF UNLICENSED MEDICINES AND OFF-LABEL MEDICINES WHERE A LICENSED MEDICINE IS AVAILABLE NHS Scotland Directors of Pharmacy and Scottish Association of Medical Directors USE OF UNLICENSED MEDICINES AND OFF-LABEL MEDICINES WHERE A LICENSED MEDICINE IS AVAILABLE CONSENSUS STATEMENT This consensus

More information

North of England Cancer Network. Policies and Procedures. Standards for the Safe Use of Oral Anticancer Medicines

North of England Cancer Network. Policies and Procedures. Standards for the Safe Use of Oral Anticancer Medicines \ North of England Cancer Network Policies and Procedures Standards for the Safe Use of Oral Anticancer Medicines NECN Oral Anticancer medicine Policy version 1.6 Page 1 of 17 Issue Date: Feb 2017 Contents

More information

Essential Shared Care Agreement: Melatonin (Circadin, Bio-Melatonin)

Essential Shared Care Agreement: Melatonin (Circadin, Bio-Melatonin) Ref No: E056 Essential Shared Care Agreement: Melatonin (Circadin, Bio-Melatonin) Please complete the following details: Patient s name, address, date of birth, and either complete when the consultant

More information

Job Title Name Signature Date. Director of Nursing Angela Wallace Signed Angela Wallace 30/6/2014

Job Title Name Signature Date. Director of Nursing Angela Wallace Signed Angela Wallace 30/6/2014 PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN FORTH VALLEY Protocol Number 445 Version 1 Date protocol prepared: June 2014 Date protocol due

More information

SHARED CARE AGREEMENT: MELATONIN (CHILDREN)

SHARED CARE AGREEMENT: MELATONIN (CHILDREN) NB: This document should be read in conjunction with the current Summary of Product Characteristics (SPC) where appropriate. DRUG AND INDICATION: Generic drug name: Formulations: MELATONIN 3mg immediate

More information

SHARED CARE GUIDELINE

SHARED CARE GUIDELINE SHARED CARE GUIDELINE Shared Care Guideline for the treatment of Tourette s Syndrome and other tic disorders in children and adolescents. Scope: Version: Pennine Care NHS Foundation Trust NHS Bury NHS

More information

MERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES. MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) KEY ISSUES

MERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES. MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) KEY ISSUES MERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) Medicines Management Services aim to ensure that (i) Service users receive their medicines

More information

Patient Group Directions (PGDs)

Patient Group Directions (PGDs) Patient Group Directions (PGDs) Document level: Trustwide (TW) Code: MP2 Issue number: 4 Lead executive Authors details Type of document Target audience Document purpose Medical Director Senior Clinical

More information

DRAFT. Consultees are asked to consider and comment on the CEPP National Audit: Antipsychotics in Dementia document.

DRAFT. Consultees are asked to consider and comment on the CEPP National Audit: Antipsychotics in Dementia document. Enclosure No: Agenda item No: Author: Contact: xx/xxxxx/xxxx0918 xx CEPP National Audit: Antipsychotics in Dementia All Wales Therapeutics and Toxicology Centre Tel: 02920 71 6900 awttc@wales.nhs.uk 1.0

More information

Appendix 4I - Melatonin Guidance for the treatment of sleep-wake cycle disorders in children

Appendix 4I - Melatonin Guidance for the treatment of sleep-wake cycle disorders in children Appendix 4I - Melatonin Guidance for the treatment of sleep-wake cycle disorders in children Background Sleep disturbance in children with neurological or behavioural disorders is common and can be a major

More information

Patient Group Directions Policy

Patient Group Directions Policy Patient Group Directions Policy Category: Summary: Equality Analysis undertaken: Valid From: Date of Next Review: Approval Date/ Via: Distribution: Related Documents: Author(s): Further Information: This

More information

Prescribing Framework for Rivastigmine in the Treatment and Management of Dementia

Prescribing Framework for Rivastigmine in the Treatment and Management of Dementia Hull & East Riding Prescribing Committee Prescribing Framework for Rivastigmine in the Treatment and Management of Dementia Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker)

More information

SHARED CARE GUIDELINE

SHARED CARE GUIDELINE SHARED CARE GUIDELINE Methylphenidate in the treatment of Attention Deficit Hyperactivity Disorder in Children, Young People and Adults Implementation Date: June 2015 Review Date: June 2017 This guidance

More information

Good Practice Guidance on Covert Administration of Medication

Good Practice Guidance on Covert Administration of Medication Good Practice Guidance on Covert Administration of Medication This good practice guidance is intended to be used as a framework for care home managers and domiciliary care providers in drawing up their

More information

Use of unlicensed medicines and off-label uses

Use of unlicensed medicines and off-label uses Use of unlicensed medicines and off-label uses 25 Promoting hope and wellbeing together What is this leaflet about? Your doctor or pharmacist has given you this leaflet because a medicine that you have

More information

PRESCRIBING GUIDELINES

PRESCRIBING GUIDELINES The Maudsley The South London and Maudsley NHS Foundation Trust & Oxleas NHS Foundation Trust PRESCRIBING GUIDELINES 10th Edition David Taylor Carol Paton Shitij Kapur informa healthcare Contents Authors

More information

Guidance on Safe Prescribing of Melatonin for Sleep Disorders in Children, Young People and Adults

Guidance on Safe Prescribing of Melatonin for Sleep Disorders in Children, Young People and Adults Guidance on Safe Prescribing of Melatonin for Sleep Disorders in Children, Young People and Adults Ref: PHARM-0025-v3 Status: FINAL Document type: Guidelines Guidance on Safe Prescribing of Melatonin Page

More information

Adult Neurodevelopmental Services. ADHD Shared Protocol

Adult Neurodevelopmental Services. ADHD Shared Protocol Adult Neurodevelopmental Services ADHD Shared Protocol Issue 1: April 2016 1 2 Adult Neurodevelopmental Service Shared Care Protocol for Adult Attention Deficit Hyperactivity Disorder (ADHD) 1. BACKGROUND

More information

Smoking Cessation Pharmacotherapy Guidelines

Smoking Cessation Pharmacotherapy Guidelines Smoking Cessation Pharmacotherapy Guidelines INTRODUCTION This guideline is based on public health guidance 10 Smoking Cessation Services issued by the National Institute for Health and Clinical Excellence

More information

ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride (South Staffordshire Only)

ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride (South Staffordshire Only) E099 ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride (South Staffordshire Only) NOTE: Please complete details on P1 &3 Send one copy to GP, Patient and

More information

Bournemouth, Dorset and Poole Prescribing Forum

Bournemouth, Dorset and Poole Prescribing Forum SHARED CARE GUIDELINES FOR PRESCRIBING OF METHYLPHENIDATE IN ATTENTION DEFICIT HYPERACTIVITY DISORDER IN CHILDREN INDICATION Methylphenidate is generally regarded as a first line choice of treatment for

More information

Factsheet. Buccolam (midazolam) 10mg in 2mL oromucosal solution. Management of seizures in adult patients

Factsheet. Buccolam (midazolam) 10mg in 2mL oromucosal solution. Management of seizures in adult patients North Central London Joint Formulary Committee Factsheet Buccolam (midazolam) 10 mg in 2 ml oromucosal solution Management of seizures in adult patients Start date: May 2017 Review date: May 2020 Document

More information

Professor Tony Holland, Department of Psychiatry, University of Cambridge

Professor Tony Holland, Department of Psychiatry, University of Cambridge INFORMATION SHEET The Use of Medication for Challenging Behaviour Professor Tony Holland, Department of Psychiatry, University of Cambridge Introduction Challenging behaviours displayed by people with

More information

Medicines Optimisation Strategy

Medicines Optimisation Strategy Clinical Reducing Dosing Errors with Opioid Medicines (Controlled Drug SOP): Document Control Summary Status: Version: Author/Owner/Title: Approved by: Ratified: Related Trust Strategy and/or Strategic

More information

This shared care protocol covers when atypical antipsychotics are prescribed for the treatment of

This shared care protocol covers when atypical antipsychotics are prescribed for the treatment of SHARED CARE PROTOCOL for ATYPICAL ANTIPSYCHOTICS SCOPE Greater Manchester West Mental health NHS Foundation Trust Bolton Primary Care Trust Salford Primary Care Trust Trafford Primary Care Trusts Issue

More information

Policy and Procedure for the Development, Approval and Implementation of Patient Group Directions in NHS Haringey Clinical Commissioning Group

Policy and Procedure for the Development, Approval and Implementation of Patient Group Directions in NHS Haringey Clinical Commissioning Group BEFORE USING THIS POLICY ALWAYS ENSURE YOU ARE USING THE MOST UP TO DATE VERSION Policy and Procedure for the Development, Approval and Implementation of Patient Group Directions in NHS Haringey Clinical

More information

Quality, Safety and Sourcing in Unlicensed Medicines

Quality, Safety and Sourcing in Unlicensed Medicines Quality, Safety and Sourcing in Unlicensed Medicines with Andrew Trouton Managing Director, UL Medicines Agenda Welcome What is an unlicensed medicine? When should you consider using an unlicensed medicine?

More information

PATIENT GROUP DIRECTION for the Supply of: Varenicline (Champix ) tablets. By: Accredited Pharmacists

PATIENT GROUP DIRECTION for the Supply of: Varenicline (Champix ) tablets. By: Accredited Pharmacists PATIENT GROUP DIRECTION for the Supply of: Varenicline (Champix ) tablets By: Accredited Pharmacists In: Community Pharmacies in [insert area] accredited by [insert council] It is the responsibility of

More information

for adults engaged with the Family Wellbeing Service Isle of Wight In Community Pharmacy for Isle of Wight Public Health Commissioned Services

for adults engaged with the Family Wellbeing Service Isle of Wight In Community Pharmacy for Isle of Wight Public Health Commissioned Services The supply of Champix (Varenicline) Tablets 500mcg and 1mg by registered community pharmacists for smoking cessation / management of nicotine withdrawal for adults engaged with the Family Wellbeing Service

More information

Prescribing Framework for Galantamine in the Treatment and Management of Dementia

Prescribing Framework for Galantamine in the Treatment and Management of Dementia Hull & East Riding Prescribing Committee Prescribing Framework for Galantamine in the Treatment and Management of Dementia Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker)

More information

SHARED CARE GUIDELINE

SHARED CARE GUIDELINE SHARED CARE GUIDELINE Title: Prescribing and/ or Monitoring of Antipsychotics Scope: Pennine Care NHS Foundation Trust NHS Bury NHS Oldham NHS Heywood, Middleton and Rochdale NHS Stockport NHS Tameside

More information

Datix Ref:

Datix Ref: Title Document Details Shared Care Agreement: Antipsychotics (Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride or Asenapine) Trust Ref No 2081-38933 Local Ref (optional) Main points the document

More information

Conduct Disorder in Children and Young People (CYP 5-18 years of age) RISPERIDONE Effective Shared Care Agreement (ESCA)

Conduct Disorder in Children and Young People (CYP 5-18 years of age) RISPERIDONE Effective Shared Care Agreement (ESCA) E102 Conduct Disorder in Children and Young People (CYP 5-18 years of age) RISPERIDONE Effective Shared Care Agreement (ESCA) Patient details Name: Date of birth: NHS number: Contact details Specialist:

More information

The Maudsley Prescribing Guidelines in

The Maudsley Prescribing Guidelines in The Maudsley Prescribing Guidelines in 11th Edition David Taylor Director of Pharmacy and Pathology South London and Maudsley NHS Foundation Trust; Professor King's College London, London, UK Paton Chief

More information

Non-Prescription Medicinal Products Containing Codeine: Guidance for Pharmacists on Safe Supply to Patients

Non-Prescription Medicinal Products Containing Codeine: Guidance for Pharmacists on Safe Supply to Patients Non-Prescription Medicinal Products Containing Codeine: Guidance for Pharmacists on Safe Supply to Patients Pharmaceutical Society of Ireland Version 3 October 2017 Updates made following the enactment

More information

PROCEDURE REF NO SABP/EXECUTIVE BOARD/0017

PROCEDURE REF NO SABP/EXECUTIVE BOARD/0017 PROCEDURE REF NO SABP/EXECUTIVE BOARD/0017 NAME OF GUIDELINE REASON FOR GUIDELINE WHAT THE GUIDELINE WILL ACHIEVE? WHO NEEDS TO KNOW ABOUT IT? Medicines Guideline: Hypnotic Medication Compliance with NICE

More information

Drug Misuse and Dependence Guidelines on Clinical Management

Drug Misuse and Dependence Guidelines on Clinical Management Department of Health Scottish Office Department of Health Welsh Office Department of Health and Social Services, Northern Ireland Drug Misuse and Dependence Guidelines on Clinical Management An Executive

More information

Benzodiazepines: risks, benefits or dependence

Benzodiazepines: risks, benefits or dependence Benzodiazepines: risks, benefits or dependence A re-evaluation Council Report CR 59 January 1997 Royal College of Psychiatrists, London Due for review: January 2002 1 Contents A College Statement 3 Benefits

More information

Bournemouth, Dorset and Poole Prescribing Forum

Bournemouth, Dorset and Poole Prescribing Forum SHARED CARE GUIDELINE FOR THE USE OF ATOMOXETINE IN ADULTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER INDICATION Atomoxetine is a non-stimulant non-amphetamine inhibitor of noradrenaline reuptake. It

More information

SHARED CARE GUIDELINE

SHARED CARE GUIDELINE SHARED CARE GUIDELINE Title: Lithium Treatment in Adults aged 18-65 years Scope: Pennine Care NHS Foundation Trust NHS Bury NHS Oldham NHS Heywood, Middleton and Rochdale NHS Stockport NHS Tameside & Glossop

More information

The treatment of bipolar disorder in adults, children and adolescents

The treatment of bipolar disorder in adults, children and adolescents DRAFT FOR CONSULTATION The treatment of bipolar disorder in adults, children and adolescents The paragraphs in the draft are numbered for the purposes of consultation. The final version will not contain

More information

S H A R E D P R E S C R I B I N G G U I D E L I N E

S H A R E D P R E S C R I B I N G G U I D E L I N E S H A R E D P R E S C R I B I N G G U I D E L I N E Introduction This shared prescribing guideline for the second generation antipsychotic medications listed above has been developed with due consideration

More information

Safe transfer of prescribing guidance

Safe transfer of prescribing guidance Safe transfer of prescribing guidance TEWV Prescriber Summary Application required before prescribing Products requiring an application, before prescribing, using the single application form Unlicensed

More information

Guidance on Bulk Prescribing for Care Home Patients

Guidance on Bulk Prescribing for Care Home Patients Guidance on Bulk Prescribing for Care Home Patients Introduction Many patients in care homes taking medicines when required (PRN) can inevitably present problems for the prescriber in determining the quantity

More information

ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride or Asenapine

ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride or Asenapine Ref No: E053 ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride or Asenapine NOTE: Please complete details on P1 &3 Send one copy to GP, Patient and file

More information

Guidance on Consent to Treatment Documentation for Medication Patient s Detained under the Mental Health Act

Guidance on Consent to Treatment Documentation for Medication Patient s Detained under the Mental Health Act Guidance on Consent to Treatment Documentation for Medication Patient s Detained under the Mental Health Act This guidance is intended for Coventry and Warwickshire Partnership Trust staff to use when

More information

POLICY DOCUMENT. Pharmacy MMG/MPG. Approved By and Date Medicines Management roup March March 2016

POLICY DOCUMENT. Pharmacy MMG/MPG. Approved By and Date Medicines Management roup March March 2016 POLICY DOCUMENT Document Title High dose and combination antipsychotic guidance Reference Number n/a Policy Type Prescribing and Treatment Guideline Electronic File/Location Clinical Resources/Pharmacy/Prescribing

More information

Shared Care Guideline. The Management of Epilepsies in Children

Shared Care Guideline. The Management of Epilepsies in Children THE SOUTH YORKSHIRE & BASSETLAW Shared Care Guideline For The Management of Epilepsies in Children Shared care guideline developed by: Sheffield Children's NHS Foundation Trust; Dr P Baxter Consultant

More information

Melatonin shared care guideline. Document Title. Corporate: Clinical. Type of document. Brief summary of contents

Melatonin shared care guideline. Document Title. Corporate: Clinical. Type of document. Brief summary of contents Document Title Melatonin shared care guideline Type of document Corporate: Clinical Brief summary of contents Executive Director responsible for Policy: Directorate / Department responsible (author/owner):

More information

Managing Behavioural Problems in Patients with Learning Disabilities

Managing Behavioural Problems in Patients with Learning Disabilities Managing Behavioural Problems in Patients with Learning Disabilities Some people with a learning disability display behaviour that challenges. Although such behaviour is a challenge to services, family

More information

Information provided to Duchenne muscular dystrophy patient organisations regarding Raxone

Information provided to Duchenne muscular dystrophy patient organisations regarding Raxone Information provided to Duchenne muscular dystrophy patient organisations regarding Raxone (idebenone) and the Early Access to Medicines Scheme in the UK (EAMS 46555/0001) April 26 th 2018 Raxone tablets

More information

Consent to research. A draft for consultation

Consent to research. A draft for consultation Consent to research A draft for consultation 1 Consent to research About the guidance Our guidance Consent: patients and doctors making decisions together (2008) 1 sets out the principles of good practice

More information

COPYRIGHTED MATERIAL. Introduction

COPYRIGHTED MATERIAL. Introduction 1 Introduction Pharmacology is the science of drugs and their effects on biological systems. A drug can be defined as a chemical that can cause a change in a biological system; the important biological

More information

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Information Sheet

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Information Sheet DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Information Sheet The management of emergency rescue medication (buccal/ oromucosal midazolam) for children, young people and adults with prolonged or

More information

PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN TAYSIDE

PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN TAYSIDE PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN TAYSIDE GENERAL POLICY 2 PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE 4 STANDING ORDER

More information

Prescribing medications for people with a personality disorder A service evaluation of a community mental health team

Prescribing medications for people with a personality disorder A service evaluation of a community mental health team Prescribing medications for people with a personality disorder A service evaluation of a community mental health team Dr Umama Khan, Consultant Psychiatrist Dr Venkatesh Ballagere, Specialist Registrar

More information

SHARED CARE PRESCRIBING GUIDELINE

SHARED CARE PRESCRIBING GUIDELINE SHARED CARE PRESCRIBING GUIDELINE RILUZOLE for the Treatment of MOTOR NEURONE DISEASE NHS Surrey s Medicines Management Committee classification: Amber N.B. The eligibility criteria included here apply

More information

EFFECTIVE SHARED CARE AGREEMENT (ESCA)

EFFECTIVE SHARED CARE AGREEMENT (ESCA) WORKING IN PARTNERSHIP WITH EFFECTIVE SHARED CARE AGREEMENT (ESCA) DRUG NAME: ACETYLCHOLINESTERASE-INHIBITORS AND MEMANTINE INDICATION/S COVERED: Dementia in Alzheimers Disease Coastal West Sussex Traffic

More information

PATIENT GROUP DIRECTION

PATIENT GROUP DIRECTION PATIENT GROUP DIRECTION FOR THE SUPPLY OF VARENICLINE (CHAMPIX ) TO ADULTS OVER 18 YEARS OF AGE BY COMMUNITY PHARMACISTS UNDER THE PUBLIC HEALTH SERVICE - SMOKING CESSSATION SERVICE IN NHS HIGHLAND THE

More information

RELEVANT ACUTE TRUST LOGO WORKING IN PARTNERSHIP WITH

RELEVANT ACUTE TRUST LOGO WORKING IN PARTNERSHIP WITH RELEVANT ACUTE TRUST LOGO WORKING IN PARTNERSHIP WITH Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath) North East Hampshire & Farnham CCG, Crawley

More information

Clinical guideline Published: 24 September 2008 nice.org.uk/guidance/cg72

Clinical guideline Published: 24 September 2008 nice.org.uk/guidance/cg72 Attention deficit hyperactivity disorder: diagnosis and management Clinical guideline Published: 24 September 2008 nice.org.uk/guidance/cg72 NICE 2018. All rights reserved. Subject to Notice of rights

More information

Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE DRUG: LISDEXAMFETAMINE PROTOCOL NUMBER: CV 57

Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE DRUG: LISDEXAMFETAMINE PROTOCOL NUMBER: CV 57 Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE DRUG: LISDEXAMFETAMINE PROTOCOL NUMBER: CV 57 INDICATION: Attention deficit hyperactivity disorder (ADHD) as part of a

More information

Pregnancy. General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition)

Pregnancy. General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition) Pregnancy General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition) In all women of child bearing potential Always discuss the possibility of pregnancy; half of all pregnancies are unplanned

More information

If a specialist asks a GP to prescribe ADHD medication in relation to this disease, the GP should reply to this request as soon as practicable.

If a specialist asks a GP to prescribe ADHD medication in relation to this disease, the GP should reply to this request as soon as practicable. Shared Care Protocol for the Methylphenidate and the Management of Attention Deficit Hyperactivity Disorder (ADHD) for children from 4 years up to 17 years and 364 days 1.0 INTRODUCTION The medical assessment

More information

Standard Operating Procedure: Early Intervention in Psychosis Access Times

Standard Operating Procedure: Early Intervention in Psychosis Access Times Corporate Standard Operating Procedure: Early Intervention in Psychosis Access Times Document Control Summary Status: New Version: V1.0 Date: Author/Owner: Rob Abell, Senior Performance Development Manager

More information

Greater Manchester Interface Prescribing Group Shared Care Guideline

Greater Manchester Interface Prescribing Group Shared Care Guideline Greater Manchester Interface Prescribing Group Shared Care Guideline Shared Care Guideline for Melatonin Circadin Author(s)/Originator(s): Dr Rob Rifkin Paediatrician RI Adele Gothard Paediatric Pharmacist

More information

Attention deficit hyperactivity disorder

Attention deficit hyperactivity disorder Attention deficit hyperactivity disorder Diagnosis and management of ADHD in children, young people and adults Issued: September 2008 last modified: March 2013 NICE clinical guideline 72 guidance.nice.org.uk/cg72

More information

Developed By Name Signature Date

Developed By Name Signature Date Patient Group Direction 2155 version 2.0 Administration / Supply of Inhaled Salbutamol in Asthma by Registered Practitioners employed by Torbay and South Devon NHS Foundation Trust Date of Introduction:

More information

Document Title Pharmacological Management of Generalised Anxiety Disorder

Document Title Pharmacological Management of Generalised Anxiety Disorder Document Title Pharmacological Management of Generalised Anxiety Disorder Document Description Document Type Policy Service Application Trust Wide Version 1.1 Policy Reference no. POL 201 Lead Author(s)

More information

Choosing and delivering ering interventions entions for

Choosing and delivering ering interventions entions for Choosing and delivering ering interventions entions for psychosis and schizophrenia in adults bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to

More information

Authorised by Greater Medicines Management Group

Authorised by Greater Medicines Management Group SHARED CARE PROTOCOL for ATYPICAL ANTIPSYCHOTICS SCOPE Greater Manchester West Mental health NHS Foundation trust Bolton Primary Care Trust Salford Primary Care Trust Trafford Primary Care Trusts Issue

More information

Clinical Policy: Clozapine orally disintegrating tablet (Fazaclo) Reference Number: CP.PMN.12 Effective Date: Last Review Date: 02.

Clinical Policy: Clozapine orally disintegrating tablet (Fazaclo) Reference Number: CP.PMN.12 Effective Date: Last Review Date: 02. Clinical Policy: Clozapine orally disintegrating tablet (Fazaclo) Reference Number: CP.PMN.12 Effective Date: 08.01.15 Last Review Date: 02.18 Line of Business: Medicaid Revision Log See Important Reminder

More information

Template Standard Operating Procedure For: Handling of Midazolam and other controlled drugs in Dental Practices

Template Standard Operating Procedure For: Handling of Midazolam and other controlled drugs in Dental Practices Name of Dental Practice : Objectives To ensure implementation of the regulations and guidance on safe and secure handling of midazolam and other controlled drugs (CDs) Scope To cover all aspects of obtaining

More information

Issue date September 2010 (Reviewed October 2013) Clinicians from Andrew Lang Centre, Mental. Specialist Pharmacist & Formulary Pharmacist

Issue date September 2010 (Reviewed October 2013) Clinicians from Andrew Lang Centre, Mental. Specialist Pharmacist & Formulary Pharmacist Title Document Type Issue no Shared care guidelines in the Treatment of Attention Deficit/ Hyperactivity Disorders Shared Care Guidelines and Information for GPs Clinical Governance Support Team Use Issue

More information

Prescribing antipsychotics for children and adolescents

Prescribing antipsychotics for children and adolescents POMH-UK Topic 10a baseline report Prescribing antipsychotics for children and adolescents September 2010 Prepared by the Prescribing Observatory for Mental Health-UK for Coventry and Warwickshire Partnership

More information

Drug Name: Lithium Clinical Indications: Treatment and prophylaxis of mania; bipolar disorder; augmentation therapy in treatment resistant depression

Drug Name: Lithium Clinical Indications: Treatment and prophylaxis of mania; bipolar disorder; augmentation therapy in treatment resistant depression SHARED CARE PROTOCOL AND INFORMATION FOR GPS Drug Name: Lithium Clinical Indications: Treatment and prophylaxis of mania; bipolar disorder; augmentation therapy in treatment resistant depression Version:

More information

Elements for a Public Summary. VI.2.1 Overview of disease epidemiology

Elements for a Public Summary. VI.2.1 Overview of disease epidemiology VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Schizophrenia Schizophrenia is a mental disorder often characterized by abnormal social behaviour and failure to recognize what

More information

Child and Adolescent Mental Health Services (CAMHS)

Child and Adolescent Mental Health Services (CAMHS) Child and Adolescent Mental Health Services (CAMHS) Effective shared care agreement (ESCA) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) with METHYLPHENIDATE This form must be completed

More information

Costing statement. Implementing NICE guidance. January NICE clinical guideline 137

Costing statement. Implementing NICE guidance. January NICE clinical guideline 137 The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care (partial update of NICE clinical guideline 20) Costing statement Implementing NICE guidance

More information

Olanzapine Long-Acting Injection (Zypadhera ) - Guidelines for Prescribing and Administration (Version 3 May 2015)

Olanzapine Long-Acting Injection (Zypadhera ) - Guidelines for Prescribing and Administration (Version 3 May 2015) 1. Key Points Olanzapine Long-Acting Injection (Zypadhera ) - Guidelines for Prescribing and Administration (Version 3 May 2015) 1.1 Olanzapine long acting injection (LAI) is indicated for the maintenance

More information

patient group direction

patient group direction DIAZEPAM (RECTAL) v01 1/8 DIAZEPAM (RECTAL) PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care

More information

Shared Care Guideline for Olanzapine (Zyprexa )

Shared Care Guideline for Olanzapine (Zyprexa ) Shared Care Guideline for Olanzapine (Zyprexa ) Development Process This guidance has been produced by Sarah Hudson Lead Pharmacist SWYPFT following an AMBER classification status of Olanzapine by the

More information